Journal of Neural Transmission

Article	Citations
Celebrating the career of professor Zdravko Lacković: a life in neuroscience, pharmacology, and discovery	99
Alterations in metabolites in the anterior cingulate cortex and thalamus and their associations with pain and empathy in patients with chronic mild pain: a preliminary study	93
Facets of movement disorders– a tribute to Heinz Reichmann	69
Do demographic and clinical features and comorbidities affect the risk of spread to an additional body site in functional motor disorders?	62
Current perspectives on brain circuits involved in food addiction-like behaviors	62
Proteinopathies: molecular mechanisms and diagnostic perspectives	58
Cholinergic neurotransmission in the brain of streptozotocin-induced rat model of sporadic Alzheimer’s disease: long-term follow up	57
A kynurenine pathway enzyme aminocarboxymuconate-semialdehyde decarboxylase may be involved in treatment-resistant depression, and baseline inflammation status of patients predicts treatment response:	56
Movement disorders associated with diarrhoea	55
Far from being the end of the road: taking a closer look at neuropalliative care in Parkinson’s disease	48
Distinct gait dimensions are modulated by physical activity in Parkinson's disease patients	46
Contrasting features between Tourette syndrome and secondary tic disorders	44
Stress enhances heartbeat-evoked potentials, independent of continuous or intermittent theta burst stimulation of the interoceptive brain network targeting the right supramarginal gyrus: a preliminary	44
A wearable device-enabled therapeutic approach to improve joint attention in autism spectrum disorder: a prospective pilot study	43
Eye movement study in essential tremor patients and its clinical correlates	43
Dopamine agonists in the treatment of Parkinson's disease: the show must go on	41
Neuromelanin granules of the substantia nigra: proteomic profile provides links to tyrosine hydroxylase, stress granules and lysosomes	40
Pathogenesis of Parkinson’s disease: from hints from monogenic familial PD to biomarkers	39
Sitagliptin attenuates L-dopa-induced dyskinesia by regulating mitochondrial proteins and neuronal activity in a 6-OHDA-induced mouse model of Parkinson’s disease	37
Unusual delayed and prolonged arm weakness and atrophy following botulinum toxin injection for musician’s cramp: case report	36
COMT inhibition with entacapone for patients with Parkinson’s disease and motor complications: the novelty of continuous infusion	34
Comparison of inflammatory biomarker levels in neurodegenerative proteinopathies: a case-control study	34
The spectrum of behavioral disorders in amyotrophic lateral sclerosis: current view	32
Camillo Golgi’s contributions to the anatomic basis of sensitivity in tendons	31
Unravelling head tremor mechanisms: insights from speech analysis in essential tremor and cervical dystonia	30

Botulinum toxin effects on biochemical biomarkers related to inflammation-associated head and neck chronic conditions: a systematic review of clinical research	30
Bradykinesia and rigidity modulated by functional connectivity between the primary motor cortex and globus pallidus in Parkinson’s disease	28
The role of immune and inflammatory-related indicators in cognitive dysfunction and disease severity in patients with parkinson’s disease	28
The pathobiology of depression in Huntington’s disease: an unresolved puzzle	27
Site-activated multi target iron chelators with acetylcholinesterase (AChE) and monoamine oxidase (MAO) inhibitory activities for Alzheimer’s disease therapy	27
Association between autonomic dysfunction with motor and non-motor symptoms in patients with Parkinson's disease	27
Non motor Parkinson: subtypes, biomarkers, stepped care and a journal!	26
Understanding cognitive features of cervical dystonia: application of the cerebellar cognitive affective syndrome scale (CCAS-S)	26
Botulinum toxin and conservative treatment strategies in people with cervical dystonia: an online survey	25
Reduced vagal activity in borderline personality disorder is unaffected by intranasal oxytocin administration, but predicted by the interaction between childhood trauma and attachment insecurity	24
Impact of APOE and MAPT genetic profile on the cognitive functions among Amyotrophic Lateral Sclerosis Tunisian patients	24
Antipsychotic drug-induced neutropenia: results from the AMSP drug surveillance program between 1993 and 2016	24
Chronic exposure to a synthetic cannabinoid alters cerebral brain metabolism and causes long-lasting behavioral deficits in adult mice	22
A call to action: revitalizing the German parkinson’s research ecosystem post-pandemic	22
Effectiveness, safety, and quality of life outcomes of neurotoxin injections in the treatment of essential tremors: a systematic review	21
Regulation of circadian gene activity in fibroblasts from ADHD patients through Rosiglitazone: a pilot study	21
Illness perceptions in pre-operative Parkinson’s disease patients	21
MeDeMSA care study protocol: developing personalized best medical care with integrated mobile palliative and telemedicine support for individuals with multiple system atrophy	20
Constipation and pain in Parkinson’s disease: a clinical analysis	20
Axial postural abnormalities and pain in Parkinson’s disease	19
Old problems, new solutions: harnessing technology and innovation in Parkinson’s disease—evidence and experiences from Thailand	19
The relationship of early life adversity and physiological synchrony within the therapeutic triad in horse-assisted therapy	19
Inhaled levodopa for threatening impending OFF episodes in managing Parkinson’s disease	18
Insulin resistance: fueling oxidative stress and neurodegeneration	18
The corticospinal tract in multiple sclerosis: correlation between cortical excitability and magnetic resonance imaging measures	17
The brainstem reticular formation pivots abnormal neural transmission in the course of Anorexia Nervosa	17
Update on sleep disorders in advanced Parkinson’s disease: a narrative review	17
Effects of association between resveratrol and ketamine on behavioral and biochemical analysis in mice	16
Potentially inappropriate medications according to PRISCUS list and FORTA (Fit fOR The Aged) classification in geriatric psychiatry: a cross-sectional study	16
Advanced therapy in advanced Parkinson’s disease: money’s too tight to mention	16
Drug repurposing and new drug targets: perspectives for novel treatment options in mental health disorders	16
Psychological, neuroendocrine and inflammatory stress responses in women after miscarriage or stillbirth: investigating early psychobiological adaptations to potential traumatic events	16
MAOA methylation is associated with impulsive and antisocial behaviour: dependence on allelic variation, family environment and diet	15
Neuroscience and addiction research: current advances and perspectives	15
The two-network framework of number processing: a step towards a better understanding of the neural origins of developmental dyscalculia	15
Serum glial fibrillary acidic protein is elevated in early-stage late-onset essential tremor and associated with tremor progression	15
Sleep disorders among frontline nurses after the COVID-19 outbreak: a large-scale cross-sectional study	15
In situ stoichiometry amounts of p62 and poly-ubiquitin exceed the increase of alpha-synuclein during degeneration of catecholamine cells induced by autophagy inhibition in vitro	15
Small intestinal bacterial overgrowth in Alzheimer’s disease	14
Type A monoamine oxidase; its unique role in mood, behavior and neurodegeneration	14
Atrophy of cerebellar lobule VI and primary motor cortex in cervical dystonia - a region of interest-based study	14
Language in autism: domains, profiles and co-occurring conditions	14
Linking diet, gut microbiota, and metabolites to Parkinson’s disease risk: a shotgun metagenomic comparison of Japanese and Taiwanese cohorts	14
Prenatal exposure to morphine enhances excitability in locus coeruleus neurons	14
Characteristics of behavioural addiction in Parkinson’s disease patients with self-reported impulse control disorder and controls matched for levodopa equivalent dose: a matched case–control study	14
Proteinopathies associated to repeat expansion disorders	14
Autism Spectrum Disorder and auditory sensory alterations: a systematic review on the integrity of cognitive and neuronal functions related to auditory processing	14
The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone	14
The natural course of idiopathic cervical dystonia	14
Issues for patchy tissues: defining roles for gut-associated lymphoid tissue in neurodevelopment and disease	13

The vicious circle between homocysteine, methyl group-donating vitamins and chronic levodopa intake in Parkinson’s disease	13
Sexual dysfunction in men with young onset Parkinson's disease	13
Exploring developmental trajectories throughout adolescence of children with autism spectrum disorder without intellectual disability	13
Reduced cerebrospinal fluid taurine is associated with nigrostriatal dopaminergic deficits in drug-naïve Parkinson’s disease	13
From the tyrosine hydroxylase hypothesis of Parkinson’s disease to modern strategies: a short historical overview	13
Exploring transferability in psychiatric interventions: a conceptual framework	13
Sex differences in schizophrenia: a longitudinal methylome analysis	12
The impact of cerebral vasomotor reactivity on cerebrovascular diseases and cognitive impairment	12
Tips and tricks in tremor treatment	12
Increased hair cortisol in mothers of children with ADHD symptoms and psychosocial adversity background	12
Superoxide dismutase isozymes in cerebral organoids from autism spectrum disorder patients	12
Cognitive impairment in Parkinson’s disease and other parkinsonian syndromes	12
Perceived social support declines after deep brain stimulation surgery in patients with Parkinson’s disease	12
Therapeutic use of medical Cannabis in neurological diseases: a clinical update	12
Facial emotion expressivity in patients with Parkinson’s and Alzheimer’s disease	11
Transcriptional dysregulation in the cerebellum triggered by oligodendroglial α-synucleinopathy: insights from a transgenic mouse into the early disease mechanisms of MSA	11
Levodopa-induced dyskinesias in Parkinson’s disease increase cerebrospinal fluid nitric oxide metabolites’ levels	11
Fatigue in fluctuating Parkinson’s disease patients: possible impact of safinamide	11
Oligodendrocytes matter: a review of animal studies on early adversity	11
Investigation of the nonmotor symptoms in patients with STN-DBS therapy in comparison with those without STN-DBS	11
Memantine: updates from the past decade and implications for future novel therapeutic applications	11
Unveiling the link between chronic pain and misuse of opioids and cannabis	11
Maternal separation and its developmental consequences on anxiety and parvalbumin interneurons in the amygdala	11
Writing tremor in Parkinson’s disease: frequency and associated clinical features	11
Patterns of striatal dopamine depletion and motor deficits in de novo Parkinson’s disease	11
Clinimetrics of the Italian version of the Montreal Cognitive Assessment (MoCA) in adult-onset idiopathic focal dystonia	11
Parkinson’s disease, aerobic exercise and photobiomodulation: a randomised controlled trial	10
High-dose glucocorticoids in COVID-19 patients with acute encephalopathy: clinical and imaging findings in a retrospective cohort study	10
Real-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations	10
A sporadic Parkinson’s disease model via silencing of the ubiquitin–proteasome/E3 ligase component, SKP1A	10
The brain and heart-axis in neurodegeneration and cardiovascular disease	10
Usability of the digit-tracking technique in a geriatric population of inpatients with and without neurocognitive disorders: The DIGICOG-start study	10
The prevalence of gastrointestinal dysfunction and its impact on quality of life in Parkinson’s disease	10
Neuromarkers in addiction: definitions, development strategies, and recent advances	10
Depression in dementia with Lewy bodies: a critical update	10
Depression and anxiety in multiple sclerosis. Review of a fatal combination	10
Plasma prolactin and symptoms of schizophrenia	10
If you can't be with the one you love, love the one you're with (C, S, N & Y)	10
RNA sequencing of the thalamus and rostral ventral medulla in rats with chronic orofacial pain	10
Mild cognitive impairment in amyotrophic lateral sclerosis: current view	10
Botulinum toxin treatment for hemifacial spasm: harmonising neurological and aesthetic outcomes	10
Posttraumatic growth and wellbeing in three countries after COVID-19: analysis using a random intercept cross-lagged panel model	10
A smartphone-based tapping task as a marker of medication response in Parkinson’s disease: a proof of concept study	9
The effect of recombinant botulinum neurotoxin A on neuropathic pain in the spared nerve injury mouse model	9
The relationship between serum prolactin levels and cognitive function in drug-naïve schizophrenia patients: a cross-sectional study	9
SARS-CoV-2 and neurodegenerative diseases: what we know and what we don’t	9
The akinetic crisis in Parkinson´s disease- the upper end of a spectrum of subacute akinetic states	9
Pharmacological considerations for treating neuroinflammation with curcumin in Alzheimer’s disease	9
Psychotherapies in opioid use disorder: toward a step-care model	9
Catecholamines and Parkinson’s disease: tyrosine hydroxylase (TH) over tetrahydrobiopterin (BH4) and GTP cyclohydrolase I (GCH1) to cytokines, neuromelanin, and gene therapy: a historical overview	9
MEF2C gene variations are associated with ADHD in the Chinese Han population: a case–control study	9
Advanced is advanced is advanced is advanced	9
Differential diagnosis of Huntington’s disease− neurological aspects of NKX2-1-related disorders	9
Mild cognitive impairment in Huntington’s disease: challenges and outlooks	9
Mediating roles of attention-deficit/hyperactivity disorder symptom severity and self-control on the relationship between adverse childhood experiences and adult aggression	9
The heterogeneity of Parkinson’s disease	9
Motor and non-motor improvements following short-term multidisciplinary day-clinic care in Parkinson´s disease	9
Environmental opportunities facilitating cognitive development in preschoolers: development of a multicriteria index	9
Correction: The neural structures of theory of mind are valence-sensitive: evidence from three tDCS studies	9
Treatment; Moussa B.H. Youdim	9
Correlation between the MNCD classification-based staging of Parkinson’s disease and quality of life: a cross-sectional study	9
The pathobiological basis of depression in Parkinson disease: challenges and outlooks	9
Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice	9
Association of polygenic risk scores, traumatic life events and coping strategies with war-related PTSD diagnosis and symptom severity in the South Eastern Europe (SEE)-PTSD cohort	8
Facial emotion recognition deficits are associated with hypomimia and related brain correlates in Parkinson’s disease	8
Cognition and Activity of Daily Living Function in people with Parkinson’s disease	8
Mild cognitive impairment in multiple system atrophy: a brain network disorder	8
Drug interactions in a sample of inpatients diagnosed with cannabis use disorder	8
From parents to children: associations of traffic risks with impulsivity, family relationships and serotonin transporter genotype	8
Locus Coeruleus magnetic resonance imaging: a comparison between native-space and template-space approach	8
The efficacy of acoustic-based articulatory phenotyping for characterizing and classifying four divergent neurodegenerative diseases using sequential motion rates	8
Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone	8
Genes critical for development and differentiation of dopaminergic neurons are downregulated in Parkinson’s disease	8
Neurogenic orthostatic hypotension in Parkinson’s disease: is there a role for locus coeruleus magnetic resonance imaging?	8
The sex-specific relationship of ghrelin and cognition in Chinese han first-episode drug-naive major depressive disorder	8
Iron and copper ions accelerate and modify dopamine oxidation to eumelanin: implications for neuromelanin genesis	8
Parkinson´s day-clinic: which patients should be selected and what services should be offered for successful therapy?	8
Optimised endoscopic access for intrajejunal levodopa application in idiopathic Parkinson's syndrome	8
Driving innovation in addiction treatment: role of transcranial magnetic stimulation	8
Polymorphisms of COMT and CREB1 are associated with treatment-resistant depression in a Chinese Han population	8

Concomitant pathologies and their impact on Huntington’s disease. A brief review of current evidence	7
Association between alcohol consumption and mortality in Parkinson’s disease	7
The impact of short-term blood pressure variability on cognitive decline in Parkinson’s disease patients without co-morbidities	7
Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson’s disease	7
Time-course of decline in different cognitive domains in Parkinson’s disease: a retrospective study	7
Clinical correlates of pareidolias and color discrimination deficits in idiopathic REM sleep behavior disorder and Parkinson’s disease	7
Repurposing drugs against Alzheimer’s disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?	7
Neurodevelopmental disorders (NDD) without boundaries: research and interventions beyond classifications	7
Plasma concentrations of anti-inflammatory cytokine TGF-β are associated with hippocampal structure related to explicit memory performance in older adults	7
A structured framework for emotion-cognition dynamics: Implications for assessment and intervention	7
Interrater reliability of motor severity scales for hemifacial spasm	7
Don’t forget about tau: the effects of ApoE4 genotype on Alzheimer’s disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment—data from the Dementia Competence Network	7
Identification of DAGLB variants in Japanese early-onset Parkinson’s disease	7
Deep brain stimulation in progressive supranuclear palsy: a dead-end story? A narrative review	7
Genetic and environmental mouse models of autism reproduce the spectrum of the disease	7
Diagnostic and therapeutic challenges in PD-associated non-motor symptoms: the roles of neurologists and consultant physicians	7
GBA-associated PD: chances and obstacles for targeted treatment strategies	7
Bioinformatics approach reveals the critical role of the NOD-like receptor signaling pathway in COVID-19-associated multiple sclerosis syndrome	7
Nicotinic regulation of microglia: potential contributions to addiction	7
Botulinum toxin therapy: past, present and future developments	7
Should continuous dopaminergic stimulation be a standard of care in advanced Parkinson’s disease?	7
MicroRNAs as biomarkers and molecular mediators of cognitive dysfunction in schizophrenia	7
Tools and criteria to select patients with advanced Parkinson’s disease for device-aided therapies: a narrative review	7
Probing the properties of PTEN specific botulinum toxin type E mutants	7
Motor and non-motor fluctuations in Parkinson’s disease: the knowns and unknowns of current therapeutic approaches	6
New trends in the research of psychiatric and neurodegenerative diseases: a tribute to Melita Salkovic-Petrisic	6
Reduced interleukin-6 stress reactivity in male physicians with occupational burnout	6
Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson’s disease	6
Correction to: Common network effect‑patterns after monoamine reuptake inhibition in dissociated hippocampus cultures	6
Correction: Insulin resistance: fueling oxidative stress and neurodegeneration	6
Sex- and age-specific prevalence and risk factors of depressive symptoms in Parkinson’s disease	6
Parkinson's Disease Multidisciplinary Complex Therapy (PD-MCT): appreciation of its current function for the treatment of people with Parkinson’s disease in Germany and the needs of future development	6
Insights into insulin signalling and oxidative stress in the Tg2576 mouse model of familial Alzheimer’s disease: effects of chronic oral galactose administration	6
Serum NfL and CHI3L1 for ALS and parkinsonian disorders in the process of diagnosis	6
Correction: Revolutionizing our understanding of Parkinson’s disease: Dr. Heinz Reichmann’s pioneering research and future research direction	6
The relationship between sphingomyelin and ceramide levels and soft neurological signs in ADHD	6
Insulin signaling disruption exacerbates memory impairment and seizure susceptibility in an epilepsy model with Alzheimer’s disease-like pathology	6
A cross-language speech model for detection of Parkinson’s disease	6
Toxic interactions between dopamine, α-synuclein, monoamine oxidase, and genes in mitochondria of Parkinson’s disease	6
Non-motor symptoms burden in motor-fluctuating patients with Parkinson’s disease may be alleviated by safinamide: the VALE-SAFI study	6
Randomized controlled trials on the use of cannabis-based medicines in movement disorders: a systematic review	6
Vascular parkinsonism: an update	6
Clozapine-associated adverse drug reactions in 38,349 psychiatric inpatients: drug surveillance data from the AMSP project between 1993 and 2016	6
Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry	6
Essential tremor plus rest tremor: current concepts and controversies	6
Predisposing factors to pattern change in cervical dystonia	6
Multilevel and multimodal biobehavioral methods in the study of stress, trauma, and resilience: a systems approach	5
Viruses, parkinsonism and Parkinson’s disease: the past, present and future	5
The neural structures of theory of mind are valence-sensitive: evidence from three tDCS studies	5
Steroid hormone pathways, vitamin D and autism: a systematic review	5
Oculometric measures as a tool for assessment of clinical symptoms and severity of Parkinson’s disease	5
Current trends in basic research on Parkinson’s disease: from mitochondria, lysosome to α-synuclein	5
Movement disorders: a brief overview from an evolutionary perspective	5
Treadmill training and physiotherapy similarly improve dual task gait performance: a randomized-controlled trial in Parkinson’s disease	5
ADHD and associated psychopathology in older adults in a German community sample	5
Excessive psychological stress preceding the onset of idiopathic cervical dystonia	5
Mitochondrial dysfunction in Parkinson’s disease	5
Levodopa may modulate specific speech impairment in Parkinson's disease: an fMRI study	5
Psychological outcomes of COVID-19 survivors at sixth months after diagnose: the role of kynurenine pathway metabolites in depression, anxiety, and stress	5
The heterogeneity of late-life depression and its pathobiology: a brain network dysfunction disorder	5
Effects of levodopa–entacapone–carbidopa intrajejunal infusion on non-motor symptoms of advanced Parkinson’s disease—interim analysis of the ELEGANCE study	5
Prof. DDr. Gregor K. Wenning (1964–2024)	5
Possible improvement of social adjustment after subthalamic deep brain stimulation in people with Parkinson’s disease? A systematic review and meta-analysis	5
Editorial for Emeritus Professor Yoshikuni Mizuno	5
Cumulative hardship: the role of perceived injustice in linking war-related trauma and discrimination with mental health	5
Neurobiological mechanisms of dialectical behavior therapy and Morita therapy, two psychotherapies inspired by Zen	5
Is the vertex a good control stimulation site? Theta burst stimulation in healthy controls	5
Brain instability in dynamic functional connectivity in schizophrenia	5
Disease modification in Parkinsonism: obstacles and ways forward	5
Neural bases characterizing chronic and severe upper-limb motor deficits after brain lesion	5
Clinical and kinematic characterization of parkinsonian soft signs in essential tremor	5
Temporal onset of non-motor symptoms and the body-first/brain-first dichotomy in Parkinson’s disease: a cross-sectional single center experience	5
Behavioral disorders in Parkinson disease: current view	5
The specific NQO2 inhibitor, S29434, only marginally improves the survival of dopamine neurons in MPTP-intoxicated mice	5
Cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT), and Morita therapy (MT); comparison of three established psychotherapies and possible common neural mechanisms of psychothe	4
Elevated levels of cerebrospinal fluid soluble triggering receptor expressed on myeloid cells 2 in multiple system atrophy: a marker of disease-associated microglial activation	4
Special issue in honor of Peter Riederer at the occasion of his 80th birthday	4
Neuroscience in addiction research	4
Altered domain-specific striatal functional connectivity in patients with Parkinson’s disease and urinary symptoms	4
Increased blood-brain barrier permeability is associated with dysfunctional α band connectivity in early-stage Parkinson’s disease	4
Genetic testing for Parkinson’s disease in clinical practice	4
Therapeutic drug monitoring in children and adolescents with schizophrenia-spectrum, affective, behavioural, tic and other psychiatric disorders treated with aripiprazole: results of the TDM-VIGIL pha	4
Approaching therapy of Alzheimer’s disease via the antidiabetic drug liraglutide—a study with streptozotocin intracerebroventricularly treated Wistar rats	4
Prevalence and impact of comorbidities in amyotrophic lateral sclerosis	4
The effectiveness of non-invasive brain stimulation in treatment of major depressive disorder (MDD): a systematic review and transfer analysis	4
Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson’s disease: post-hoc analysis of a Japanese phase III study	4
The link between Wnt-related, stress-related, and circadian genes in the dermal fibroblasts of individuals with attention-deficit hyperactivity disorder	4
Peter Riederer, a translational neurobiochemist	4
Declining incidence of Parkinson’s disease in Israel (2002–2021)	4
The brain-first vs. body-first model of Parkinson’s disease with comparison to alternative models	4
Spasmodic dysphonia: the need for a combined neurological and phoniatric approach	4
Action impulsivity and attention deficits in patients at an early stage of Huntington disease	4
More than fear? Brain activation patterns of dental phobic patients before and after an exposure-based treatment	4
A 12-month prospective real-life study of opicapone efficacy and tolerability in Emirati and non-White subjects with Parkinson’s disease based in United Arab Emirates	4
The ‘α-synucleinopathy syndicate’: multiple system atrophy and Parkinson’s disease	4